Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
October 1, 2007
- Biopharmaceuticals to Account for 45% of Sales in 2010: Wyeth
October 1, 2007
- 41% of Adults Have Undergone Upper GI Endoscopy: Olympus Awareness Survey
October 1, 2007
- Pharma Summit at Bio Japan 2007
October 1, 2007
- DSM to Expand Lineup of Materials for Devices in the Field of Orthopedic Surgery
October 1, 2007
- MTPC to Develop Flexible Computer Systems to Quickly Respond to Market Changes
October 1, 2007
- Tokyo Boeki Machinery to Launch BIOLIS mini
October 1, 2007
- ASKA Licenses New Oral Formulation Technology from LINTEC
October 1, 2007
- Olympus to Launch Capsule Endoscope System in US
October 1, 2007
- Oncodesign Hosts Japanese Pharma Industry Group
October 1, 2007
- R&D NEWS IN BRIEF
October 1, 2007
- Environment to Allow Both Work and Childcare Needed to Retain Female MRs
October 1, 2007
- Feasibility Studies for Joint Clinical Trials in Asia Increasing: CMIC
October 1, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 1, 2007
- Chuikyo Members Favor Changes in Comparator Drug Selection Rule
October 1, 2007
- JSMD Issues Official Statement on Risk of Suicide due to Antidepressants
October 1, 2007
- Novartis to Apply for Withdrawal of Depression as Indication for Ritalin
October 1, 2007
- Scheduled Replacement Therapy Better for Hemophiliacs: Bayer Yakuhin Seminar
October 1, 2007
- GENERICS NEWS IN BRIEF
October 1, 2007
- Appropriate Diagnosis and Treatment of Irritable Bowel Syndrome Needed: Seminar
October 1, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…